Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT Infrastructure II in connection with the Hector Rail group’s divestment of GB Railfreight (1)
Mandate

Vinge advises EQT Infrastructure II in connection with the Hector Rail group’s divestment of GB Railfreight

September 23, 2019 M&A

GB Railfreight was acquired by EQT Infrastructure II, through its current Swedish portfolio company Hector Rail, in November 2016 and is the third largest rail freight operator in the United Kingdom, with a turnover in excess of GBP 200m.

GB Railfreight is one of the fastest growing companies in the UK railway sector and transports goods and provides services for a wide range of customers.

 
Vinge has advised EQT Infrastructure II in connection with the restructuring of the Hector Rail group and in connection with the divestment of its UK subsidiary GB Railfreight. 
 
The transaction is expected to close mid‑October 2019.
 
Vinge’s team consisted of Daniel Rosvall, Karl Klackenberg, Hannes Pettersson and Milad Kamali. 
 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025